Related Experiment Video

Updated: Sep 30, 2026

Isolation of Leukocytes from Human Breast Milk for Use in an Antibody-dependent Cellular Phagocytosis Assay of HIV Targets
08:12

Isolation of Leukocytes from Human Breast Milk for Use in an Antibody-dependent Cellular Phagocytosis Assay of HIV Targets

Published on: September 6, 2019

Kinetics of maternal hepatitis a antibody decay in infants: implications for vaccine use

Jay M Lieberman1, Swei-ju Chang Chang, Susan Partridge

  • 1Miller Children's Hospital Long Beach, CA 90806, USA. jay_lieberman@hotmail.com

The Pediatric Infectious Disease Journal
|June 22, 2002
PubMed

Insights

Maternal hepatitis A antibody levels remain high in infants for the first six months. However, antibody decay is significant by 12 months of age, impacting infant immunity.

Area of Science:

  • Immunology
  • Pediatrics
  • Public Health

Background:

  • Hepatitis A is a significant public health concern.
  • Maternal antibodies play a crucial role in protecting infants from infectious diseases during early life.
  • Understanding the duration of maternal hepatitis A antibody protection is essential for vaccination strategies.

Purpose of the Study:

  • To evaluate the decay kinetics of maternal hepatitis A antibodies in infants.
  • To determine the seropositivity rates of hepatitis A antibodies in infants at different ages.
  • To assess the duration of passive immunity conferred by maternal hepatitis A antibodies.

Main Methods:

  • A seroepidemiologic study was conducted.
  • Serum samples were collected from 200 infants at 2, 4, 6, and 12 months of age.
  • Hepatitis A antibody titers were measured using standardized immunoassays.

Main Results:

  • At 2 months, 38% of infants were hepatitis A antibody-positive with a geometric mean titer of 2634 mIU/ml.
  • Seropositivity rates remained high at 4 months (100%) and 6 months (95%).
  • A significant decay in antibody levels was observed by 12 months, with a seropositivity rate of 39%.

Conclusions:

  • Maternal hepatitis A antibodies provide substantial protection during the first six months of life.
  • Antibody levels decline significantly by 12 months of age.
  • These findings have implications for the timing of hepatitis A vaccination in infants.

More Related Videos

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

Related Concept Videos

Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Vaccinations01:51

Vaccinations

Overview
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Transcytosis of IgG01:15

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...